Theodoros Karantanos

List of Publications by Year
in descending order

66	2,933	257357 24	175177 52
papers	citations	h-index	g-index

71	71	71	6027
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene, 2013, 32, 5501-5511.	2.6	646
2	Fecal Colonization With Extended-spectrum Beta-lactamaseâ€“ProducingEnterobacteriaceaeand Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. Clinical Infectious Diseases, 2016, 63, 310-318.	2.9	359
3	Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level. European Urology, 2015, 67, 470-479.	0.9	225
4	Androgen receptor inhibitorâ€“induced â€œBRCAnessâ€•and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Science Signaling, 2017, 10, .	1.6	200
5	Immunotherapy comes of age: Immune aging & checkpoint inhibitors. Journal of Geriatric Oncology, 2017, 8, 229-235.	0.5	108
6	Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion. American Journal of Surgical Pathology, 2018, 42, 1121-1126.	2.1	96
7	Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Reports, 2017, 18, 1970-1981.	2.9	83
8	DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene, 2015, 34, 2815-2822.	2.6	81
9	Targeting Poly(ADP-Ribose) Polymerase and the c-Mybâ€“Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. Science Signaling, 2014, 7, ra47.	1.6	73
10	Regulation of T Cell Differentiation and Function by EZH2. Frontiers in Immunology, 2016, 7, 172.	2.2	70
11	Current insights in to the pathophysiology of Irritable Bowel Syndrome. Gut Pathogens, 2010, 2, 3.	1.6	67
12	Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast, 2012, 21, 534-538.	0.9	66
13	The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clinical and Translational Oncology, 2019, 21, 206-212.	1.2	59
14	Clock genes: Their role in colorectal cancer. World Journal of Gastroenterology, 2014, 20, 1986.	1.4	53
15	Do Anastomotic Leaks Impair Postoperative Health-related Quality of Life After Rectal Cancer Surgery? A Case-matched Study. Diseases of the Colon and Rectum, 2014, 57, 158-166.	0.7	44
16	Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Oncotarget, 2016, 7, 85624-85640.	0.8	44
17	Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Advances, 2020, 4, 2567-2576.	2.5	37
18	Association of the clock genes polymorphisms with colorectal cancer susceptibility. Journal of Surgical Oncology, 2013, 108, 563-567.	0.8	35

#	Article	IF	Citations
19	Expression of Clock Genes in Patients with Colorectal Cancer. International Journal of Biological Markers, 2013, 28, 280-285.	0.7	35
20	Prospective evaluation of health-related quality of life after laparoscopic colectomy for cancer. Techniques in Coloproctology, 2013, 17, 27-38.	0.8	34
21	Post-colectomy assessment of gastrointestinal function: a prospective study on colorectal cancer patients. Techniques in Coloproctology, 2013, 17, 525-536.	0.8	32
22	Synbiotics and gastrointestinal function-related quality of life after elective colorectal cancer resection. Annals of Gastroenterology, 2016, 29, 56-62.	0.4	32
23	Immune response after laparoscopic colectomy for cancer: a review. Gastroenterology Report, 2013, 1, 85-94.	0.6	30
24	DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer. Communications Biology, 2021, 4, 1289.	2.0	30
25	Probiotics, Prebiotics, Synbiotics: Is There Enough Evidence to Support Their Use in Colorectal Cancer Surgery?. Digestive Surgery, 2012, 29, 426-438.	0.6	29
26	GLIPR1-Î”TM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Molecular Cancer, 2015, 14, 122.	7.9	24
27	Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance. Advances in Experimental Medicine and Biology, 2019, 1139, 153-169.	0.8	23
28	Serotonin Transporter and G Protein Beta 3 Subunit Gene Polymorphisms in Greeks with Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2011, 56, 3276-3280.	1.1	22
29	Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget, 2016, 7, 46321-46334.	0.8	22
30	Genderâ€related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. British Journal of Haematology, 2021, 193, 1142-1150.	1.2	21
31	Caspase 9 promoter polymorphisms confer increased susceptibility to breast cancer. Cancer Genetics, 2012, 205, 508-512.	0.2	20
32	Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease. Frontiers in Immunology, 2019, 10, 295.	2.2	20
33	Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohnâ€™s disease. World Journal of Gastroenterology, 2014, 20, 3609.	1.4	19
34	5-HT2A Receptor Gene Polymorphisms and Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2011, 45, 514-517.	1.1	16
35	Vascular endothelial growth factor and endoglin expression in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2010, 136, 703-708.	1.2	14
36	Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocrine-Related Cancer, 2016, 23, 691-698.	1.6	14

#	Article	IF	Citations
37	The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy. Blood Reviews, 2018, 32, 426-432.	2.8	12
38	Quality of Life After Laparoscopic Colectomy for Cancer. Journal of the Society of Laparoendoscopic Surgeons, 2014, 18, 225-235.	0.5	11
39	Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. Best Practice and Research in Clinical Haematology, 2021, 34, 101280.	0.7	11
40	Systemic GLIPR1-Î”TM protein as a novel therapeutic approach for prostate cancer. International Journal of Cancer, 2014, 134, 2003-2013.	2.3	10
41	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clinical Immunology, 2019, 207, 18-23.	1.4	10
42	Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. International Journal of Molecular Sciences, 2021, 22, 2595.	1.8	10
43	Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer. Cancer Biomarkers, 2015, 15, 843-850.	0.8	9
44	Inflammatory bowel disease: recent advances on genetics and innate immunity. Annals of Gastroenterology, 2011, 24, 164-172.	0.4	9
45	Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. Leukemia Research, 2020, 99, 106477.	0.4	8
46	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. Leukemia and Lymphoma, 2022, 63, 1942-1948.	0.6	8
47	The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. Science Advances, 2022, 8, eabl8952.	4.7	7
48	Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies. Blood and Lymphatic Cancer: Targets and Therapy, 2017, Volume 7, 37-52.	1.2	6
49	Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. Oncologist, 2019, 24, 146-150.	1.9	5
50	Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms. Cancers, 2021, 13, 3246.	1.7	5
51	JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function. Translational Cancer Research, 2016, 5, S1208-S1211.	0.4	5
52	GEMMs Shine a Light on Resistance to Androgen Deprivation Therapy for Prostate Cancer. Cancer Cell, 2013, 24, 11-13.	7.7	4
53	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. Biology of Blood and Marrow Transplantation, 2017, 23, 103-112.	2.0	4
54	Pyogenic Liver Abscess Due to Fusobacterium nucleatum in a Patient With Liver Hemangiomas. American Journal of the Medical Sciences, 2017, 353, 417-418.	0.4	3

#	Article	IF	Citations
55	Inflammation exerts a nonrandom risk in the acquisition and progression of the MPN: Insights from a Mendelian randomization study. EClinicalMedicine, 2020, 21, 100324.	3.2	2
56	Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. Asian Journal of Urology, 2014, 1, 30-39.	0.5	1
57	Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. Bone Marrow Transplantation, 2020, 55, 1821-1823.	1.3	1
58	Independent Association of Male Sex with Presentation and Clinical Outcomes in Myeloproliferative Neoplasms. Blood, 2018, 132, 1768-1768.	0.6	1
59	Assessing the cardiovascular risk of hormonal therapy in patients with prostate cancer. Annals of Translational Medicine, 2016, 4, 99-99.	0.7	1
60	ATM Germline Variant Increases the Risk of MPN Progression. Blood, 2019, 134, 835-835.	0.6	1
61	Gender Determines the Myeloproliferative Neoplasms Phenotype Independently of Age, Driver Mutation and JAK2V617F Burden. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S267-S268.	0.2	0
62	976. Development and Validation of a Risk Score for Predicting Cardiovascular Events in HIV-Infected Patients. Open Forum Infectious Diseases, 2019, 6, S35-S36.	0.4	0
63	Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden. Blood, 2019, 134, 837-837.	0.6	0
64	2019 Brings Biologic Understanding and Hope for Patients With TP53 Mutated Myelodysplastic Syndrome. , 2020, 17, .		0
65	Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN). Blood, 2020, 136, 40-40.	0.6	0
66	Abstract 5435: CCRL2 affects the sensitivity of MDS and secondary AML to azacitidine. Cancer Research, 2022, 82, 5435-5435.	0.4	0